Publikationen, an denen er mitarbeitet Luis Barral (2)

2022

  1. The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

    Frontiers in Pharmacology, Vol. 13

2019

  1. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats

    Biochemical Pharmacology, Vol. 170